Clinical and genetic analyses of juvenile myelomonocytic leukemia.
- Author:
Min-Hui ZENG
1
;
Xiang-Ling HE
;
Ming-Hua YANG
;
Min-Cui ZHENG
;
Wu-Qing WAN
;
Run-Ying ZOU
;
Ke-Ke CHEN
Author Information
1. Department of Hematology and Oncology, Children's Medical Center, Hunan Provincial People's Hospital/First Hospital of Hunan Normal University, Changsha 410005, China. hexiangl@163.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Child;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myelomonocytic, Juvenile;
genetics;
Leukocytes, Mononuclear;
Male;
Mutation;
Prognosis
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(4):365-369
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical and genetic features of juvenile myelomonocytic leukemia (JMML) and the association between genotype and prognosis. Methods The clinical data of 15 children who were diagnosed with JMML were collected. Next-generation sequencing was used to detect common gene mutations of JMML.
RESULTS:The male/female ratio was 6.5:1, and the age of onset was 19 months (range 2-67 months). Of the 15 children, 11 (73%) experienced disease onset before the age of 4 years, with abdominal distension and pyrexia as initial symptoms. All children had hepatosplenomegaly and superficial lymphadenectasis, with a number of peripheral blood mononuclear cells of >1.0×10/L and a percentage of juvenile cells of 1%-7% in peripheral blood smear. The percentage of bone marrow blasts + juvenile cells was <20%, and the percentage of monoblasts + promonocytes was 1%-10%. Of the 15 children, 10 (67%) had a higher level of hemoglobin F than the normal level at the corresponding age, with the highest level of 62.5%. All 15 children had the absence of Philadelphia chromosome, and one child had chromosome 7 deletion. All 15 children had a negative result of BCR/ABL fusion gene detection. PTPN11 gene mutation was found in 5 children (33%), NF1 mutation in 4 children (27%), CBL mutation in 3 children (20%), and RAS mutation in 3 children (20%). No children received regular chemotherapy, and one child underwent hematopoietic stem cell transplantation. The median follow-up time of 15 children was 18 months (range 1-48 months). Among the 15 children, 8 died (among whom 4 had PTPN11 gene mutation, 3 had NF1 mutation, and 1 had RAS mutation) and 7 survived. The children with PTPN11 mutation had the worst prognosis and the highest mortality rate, and those with CBL or NRAS mutation had a relatively good prognosis. The level of hemoglobin F was negatively correlated with survival time (r=-7.21, P=0.002).
CONCLUSIONS:In children with JMML, the type of gene mutation is associated with prognosis. The children with PTPN11 mutation often have a poor prognosis, and those with CBL or NRAS mutation have a relatively good prognosis.
